Canatu Plc · OMXHEX:CANATU
Canatu — Canatu Oyj A Ord — H1 2025 Earnings Presentation
26 slides from Canatu's earnings presentation, Aug 29, 2025
Slide 1: Half-year financial report: operational performance and competitive position strengthened
Half-year financial report (unaudited): Operational performance and competitive position strengthened, despite delay in revenue Juha Kokkonen, CEO Mikko Vesterinen, CFO Canatu half-year 2025 webcast 29 August 2025 Nedal Safwat, CDO
Slide 2: Disclaimer
Disclaimer Notice shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Each person must rely on their own examination and Canatu Plc (the “Company”) h
Slide 3: Agenda
Agenda • Highlights • Key financials • Medical Diagnostics • Outlook & targets • Q&A Juha Kokkonen Mikko Vesterinen Nedal Safwat CEO CFO CDO
Slide 4: Key messages
Key messages Competitive edge in CNT pellicles has remained strong or improved; investments in further growth accelerated. Key driver Operational progress H1 revenue Investing for growth and • Rapid AI growth is • The first CNT100 SEMI diversification • Revenue EUR 7.3 million fueling demand for rea
Slide 5: Key drivers
Key drivers Juha Kokkonen, CEO
Slide 6: The advanced chip investments are growing explosively
The advanced chip investments are growing explosively Canatu’s competitive position is strong • Advanced chips (<7nm features) are the fastest ADVANCED CHIPS growing segment in the semiconductor industry, CAGR ~20% projected to grow at roughly 20%, with logic chips growing at 10-20% and DRAM 15-25%
Slide 7: Selected highlights
Selected highlights Juha Kokkonen, CEO
Slide 8: First reactor customer approved
First reactor customer approved Reactor ready for mass production • The first 1st CNT100 SEMI reactor and equipment have received customer approval at the manufacturing site and are ready to start mass production of CNT pellicle membranes. • Before pilot and risk production, the customer must secure
Slide 9: Positive progress in CNT pellicle deployment
Positive progress in CNT pellicle deployment 3 2 1 ONGOING NEGOTIATIONS FOR NEW REACTOR 2. CUSTOMER: 1. CUSTOMER: SALES WITH BOTH EXISTING AND NEW CUSTOMERS SAT ONGOING SAT COMPLETED 1 3 5 7 PURCHASE ASSEMBLY AND FACTORY INSTALLATION AND SITE PILOT AND RISK ORDER ACCEPTANCE TEST (FAT) ACCEPTANCE TES
Slide 10: New business development
New business development Systemic assessment of new high-value applications • Accelerating new business with enhanced resources and a dedicated team—aiming for faster time-to-market of high-value applications. • Addressing new business opportunities more systematically and proactively. • Canatu was
Slide 11: Diversification of CNT technology to new application areas
Diversification of CNT technology to new application areas Next-gen solar panel applications Sensors for defense and security applications Key market drivers Key market drivers Energy efficiency driving EV adoption Preventing unauthorized access Solar power generation extending range Maintaining dat
Slide 12: Financial review
Financial review Mikko Vesterinen, CFO
Slide 13: Key figures
Key figures • During H1, we successfully completed the first REVENUE REVENUE GROSS PROFIT delivery of our CNT100 SEMI reactor, which is now 7.3M€ GROWTH 4.9M€ ready for mass production of CNT pellicle (11.1M€) -34.1% (6.9M€) membranes. • Our market position in inspection membranes GROSS MARGIN EBITD
Slide 14: Revenue by business unit
Revenue by business unit TOTAL REVENUE M€ • Semiconductor: the contribution of the inspection 22.0 membrane to the semiconductor business revenue remained solid. The final part of the first CNT100 SEMI reactor project’s revenue was recognized. • Automotive: business grew, driven by JDA with 11.1 7.3
Slide 15: Medical diagnostics
Medical diagnostics Nedal Safwat, CDO
Slide 16: Strengthening our team: Nedal Safwat, Head of BU, Medical Diagnostics
Strengthening our team: Nedal Safwat, Head of BU, Medical Diagnostics Born 1975, Ph.D. (Biochemistry), United States citizen, Management Team member 2025– Relevant work experience • Cepheid Inc., Vice President Portfolio and Program Management Office 2025 • QIAGEN Inc., Vice President, Head of Molec
Slide 17: Point-of-care diagnostics rising in healthcare
Point-of-care diagnostics rising in healthcare Point-of-care diagnostics • Point-of-care (POC) diagnostics refers to the medical testing performed at or near the site of patient care rather than in a centralized laboratory • Over the past decade, POC has emerged as a transformative approach in diagn
Slide 18: Point-of-care market trends drive demand for innovation
Point-of-care market trends drive demand for innovation PoC applications Global market USD 6.0 Bn USA market USD 3.3 Bn Increased demand for point-of-care • Decentralized healthcare moving highly complex test that are either time-sensitive, acute, or benefit from earlier intervention • Infectious di
Slide 19: Point-of-care roadmap
Point-of-care roadmap CNT Multi-modal biorecognition Medical diagnostic applications Patient care antigen Hormone monitoring and therapy Infectious diseases (markers and pathogens) DNA Versatile detection (development partnership) antibody Paracetamol detection
Slide 20: Feasibility: Canatu CNT shows high sensitivity
Feasibility: Canatu CNT shows high sensitivity Circulating tumor (Ct) DNA detection Total testosterone detection • Quantifiable measurement of total testosterone in human • High sensitivity of carbon nanotubes (CNT) biosensors spiked serum samples detecting circulating tumor DNA (ctDNA) at sub pico-
Slide 21: Outlook & targets
Outlook & targets Juha Kokkonen, CEO
Slide 22: 2025 Outlook
2025 Outlook • Canatu expects that its revenue for the financial year • In the near term, Canatu sees that there are certain 2025 will decline compared to the unaudited 2024 pro factors which affect the revenue visibility and may forma revenue of EUR 22 million. increase the volatility of the compan
Slide 23: Long-term financial targets
Long-term financial targets • Canatu’s long-term financial targets are: The following assumptions are highly important in • Over EUR 100 million revenue in 2027 achieving the long-term financial targets: • EBIT margin (adjusted for goodwill amortization in • Semiconductor (large contribution): accor
Slide 24: Key messages
Key messages Competitive edge in CNT pellicles has remained strong or improved; investments in further growth accelerated. Key driver Operational progress Investing for growth and • Rapid AI growth is fueling • The first CNT100 SEMI reactor is diversification demand for advanced chips, customer-appr
Slide 25: Q&A
Q&A CANATU
Slide 26: Thank you for your interest
Thank you for your interest Next events: • Full-year 2025: 3 March 2026 • Annual report: week 11 • CMD: week 13 • AGM: 16 April 2026 • Half-year 2026: 25 August 2026